awmsg logo



stiripentol (Diacomit®)


Reference No. 3468

Publication date:
29/11/2017


Appraisal information

stiripentol (Diacomit®) capsule


Company: Biocodex
BNF category: Central nervous system
NMG meeting date: 04/10/2017
AWMSG meeting date: 08/11/2017
   
   
Submission Type: Resubmission
Status: Recommended
Advice No: 2617
Ministerial ratification: 28/11/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Stiripentol (Diacomit®) is recommended for use within NHS Wales for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download